TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice

Du,Jinghua; Niu,Xuemin; Wang,Rongqi; Zhao,Suxian; Kong,Lingbo; Zhang,Yuguo; Nan,Yuemin

doi:10.3892/mmr.2016.4775

TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice

Authors:
- Jinghua Du
- Xuemin Niu
- Rongqi Wang
- Suxian Zhao
- Lingbo Kong
- Yuguo Zhang
- Yuemin Nan
View Affiliations

Affiliations: Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 051000, P.R. China
Published online on: January 13, 2016 https://doi.org/10.3892/mmr.2016.4775
Pages: 2159-2166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of the innate immune system is involved in the development of chronic liver diseases, including nonalcoholic steatohepatitis. Toll‑like receptor 4 (TLR4) is one of the sensors of the innate immune system. The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis. Male C57BL/6J mice were fed a methionine‑choline deficient (MCD) diet for 8 weeks to induce nonalcoholic fibrotic steatohepatitis. The PPARγ agonist, pioglitazone, and PPARγ inhibitor, GW9662, were administered to the mice, respectively. The effects of the induction of PPARγ on liver biochemistry and histology, the modulation of TLR4 and its downstream pathway, and the expression levels of inflammatory and fibrogenic genes were assessed using reverse transcription‑quantitative polymerase chain reaction and Western blot analyses. The MCD‑fed mice exhibited progressive hepatic steatosis, necrotic inflammation and fibrosis, along with increase levels of serum alanine aminotransferase and aspartate aminotransferase, accompanied by the upregulation of TLR4, the TLR4‑myeloid differentiation primary response gene 88‑dependent pathway and downstream genes, and proinflammatory and profibrotic genes; and downregulation of basic membrane protein and activin membrane‑bound inhibitor. The administration of pioglitazone was found to reverse hepatic nutritional fibrosis via restoration of the expression levels of proinflammatory and profibrotic genes in the MCD‑fed mice. The results of the present study provide novel evidence supporting the protective role of pioglitazone in ameliorating nutritional fibrotic steatohepatitis, through modulation of the TLR4‑mediated signaling pathway.

View Figures

View References

1	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
2	Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: Old questions and new insights. Science. 332:1519–1523. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kelishadi R and Poursafa P: Obesity and air pollution: Global risk factors for pediatric non-alcoholic fatty liver disease. Hepat Mon. 11:794–802. 2011. View Article : Google Scholar
4	Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J and Hultcrantz R: Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 51:595–602. 2010. View Article : Google Scholar
5	Guo J and Friedman SL: Toll like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 3:212010. View Article : Google Scholar
6	Fuentes E, Guzmán-Jofre L, Moore-Carrasco R and Palomo I: Role of PPARs in inflammatory processes associated with metabolic syndrome. Mol Med Rep. 8:1611–1616. 2013.PubMed/NCBI
7	Nan YM, Han F, Kong LB, Zhao SX, Wang RQ, Wu WJ and Yu J: Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol. 46:358–369. 2011. View Article : Google Scholar
8	Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol. 44:358–365. 2009. View Article : Google Scholar
9	Ji Y, Liu J, Wang Z, Liu N and Gou W: PPARgama agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 89:887–902. 2009. View Article : Google Scholar : PubMed/NCBI
10	Leclercq IA, Lebrun VA, Stärkel P and Horsmans YJ: Intrahepatic insulin resistance in a murine model of steatohepatitis: Effect of PPARgamma agonist pioglitazone. Lab Invest. 87:56–65. 2007. View Article : Google Scholar
11	Da Silva Morais A, Lebrun VA, Abarca-Quinones J, Brichard S, Hue L, Guigas B, Viollet B and Leclercq IA: Prevention of steatohepatitis by pioglitazone: Implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. J Hepatol. 50:489–500. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ballestri S, Lonardo A and Loria P: Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree? Hepatology. 53:2142–2143. 2011. View Article : Google Scholar : PubMed/NCBI
13	Alkhouri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE and Nobili V: Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol. 57:1312–1318. 2012. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V and Younossi ZM: Differential expression of miRNAsliver disease. Aliment Pharmacol Ther. 32:487–497. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang RQ, Nan YM, Wu WJ, Kong LB, Han F, Zhao SX, Kong L and Yu J: Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis. 10:312011. View Article : Google Scholar : PubMed/NCBI
17	Berlanga A, Guiu-Jurado E, Porras JA and Auguet T: Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 7:221–239. 2014.PubMed/NCBI
18	Hasenfuss SC, Bakiri L, Thomsen MK, Williams EG, Auwerx J and Wagner EF: Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab. 19:84–95. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xu E, Forest MP, Schwab M, Avramoglu RK, St-Amand E, Caron AZ, Bellmann K, Shum M, Voisin G, Paquet M, et al: Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPARγ. Hepatology. 59:1803–1815. 2014. View Article : Google Scholar
20	Villalpando-Arteaga EV, Mendieta-Condado E, Esquivel-Solís H, Canales-Aguirre AA, Gálvez-Gastélum FJ, Mateos-Díaz JC, Rodríguez-González JA and Márquez-Aguirre AL: Hibiscus sabdariffa L. aqueous extract attenuates hepatic steatosis through down-regulation of PPAR-γ and SREBP-1c in diet-induced obese mice. Food Funct. 4:618–626. 2013. View Article : Google Scholar : PubMed/NCBI
21	Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC and Bergheim I: Toll-like receptor 4 is involved in the development of frustose-induced hepatic steatosis in mice. Hepatology. 50:1094–1104. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC and Bergheim I: Toll-like receptors 1–9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr. 107:1727–1738. 2012. View Article : Google Scholar
23	Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H and Fukui H: Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 28:723–730. 2013. View Article : Google Scholar : PubMed/NCBI
24	Guo J and Friedman SL: Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 3:21–39. 2010. View Article : Google Scholar : PubMed/NCBI
25	Szabo G, Velayudham A, Romics L Jr and Mandrekar P: Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 29(Suppl 11): S140–S145. 2005. View Article : Google Scholar
26	Dauphinee SM and Karsan A: Lipopolysaccharide signaling in endothelial cells. Lab Invest. 86:9–22. 2006. View Article : Google Scholar
27	Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E and Szabo G: Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 300:G433–G441. 2011. View Article : Google Scholar : PubMed/NCBI
28	Aoyama T, Paik YH and Seki E: Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010:pii: 192543. 2010. View Article : Google Scholar : PubMed/NCBI
29	Baghy K, Iozzo RV and Kovalszky I: Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem. 60:262–268. 2012.PubMed/NCBI
30	Li YS, Ni SY, Meng Y, Shi XL, Zhao XW, Luo HH and Li X: Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: A new pro-fibrotic mechanism of angiotensin II. PLoS One. 8:e762892013. View Article : Google Scholar
31	Saiman Y, Agarwal R, Hickman DA, Fausther M, El-Shamy A, Dranoff JA, Friedman SL and Bansal MB: CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. 305:G375–G382. 2013.
32	Cynis H, Kehlen A, Haegele M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S and Demuth HU: Inhibition of glutaminyl cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 94:217–225. 2013.PubMed/NCBI
33	Heinrichs D, Berres ML, Nellen A, Fischer P, Scholten D, Trautwein C, Wasmuth HE and Sahin H: The chemokine CCL3 promotes experimental liver fibrosis in mice. PLoS One. 8:e661062013. View Article : Google Scholar : PubMed/NCBI
34	Gressner AM: Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: A key event in hepatic fibrogenesis. Kidney Int Suppl. 54:S39–S45. 1996.PubMed/NCBI